{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:20:20Z","timestamp":1772259620500,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.cardfail.2023.06.024","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T20:46:45Z","timestamp":1691441205000},"page":"1345-1354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial"],"prefix":"10.1016","volume":"29","author":[{"given":"MUHAMMAD SHAHZEB","family":"KHAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEFAN D.","family":"ANKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GERASIMOS","family":"FILIPPATOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JO\u00c3O PEDRO","family":"FERREIRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STUART J.","family":"POCOCK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAMES L.","family":"JANUZZI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VIJAY K.","family":"CHOPRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ILEANA L.","family":"PI\u00d1A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHAEL","family":"B\u00d6HM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PIOTR","family":"PONIKOWSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SUBODH","family":"VERMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARTINA","family":"BRUECKMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"OLA","family":"VEDIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BARBARA","family":"PEIL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FAIEZ","family":"ZANNAD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MILTON","family":"PACKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAVED","family":"BUTLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2023.06.024_bib0001","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0004","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0006","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0007","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jacc.2006.11.041","article-title":"Associations of gender and etiology with outcomes in heart failure with systolic dysfunction. a pooled analysis of 5 randomized control trials","volume":"49","author":"Frazier","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/eurjhf\/hfs026","article-title":"Gender and survival in patients with heart failure: interactions with diabetes and aetiology: results from the MAGGIC individual patient meta-analysis","volume":"14","author":"Mart\u00ednez-Sell\u00e9s","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0009","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","article-title":"Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF","volume":"7","author":"Balmforth","year":"2019","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0010","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0011","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.amjcard.2018.09.014","article-title":"Prevalence and outcomes of polyvascular (coronary, peripheral, or cerebrovascular) disease in patients with diabetes mellitus (from the SAVOR-TIMI 53 trial)","volume":"123","author":"Gutierrez","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0012","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cardfail.2023.06.024_bib0013","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/dom.14326","article-title":"Impact of polyvascular disease with and without coexistent kidney dysfunction on cardiovascular outcomes in diabetes: a post hoc analysis of EMPA-REG OUTCOME","volume":"23","author":"Verma","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0014","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ejhf.69","article-title":"Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition study","volume":"16","author":"Khan","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0015","article-title":"Impact of empagliflozin in heart failure with reduced ejection fraction in patients with ischemic versus nonischemic cause","author":"Khan","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0016","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0017","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0018","doi-asserted-by":"crossref","first-page":"e15959","DOI":"10.1097\/MD.0000000000015959","article-title":"Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction","volume":"98","author":"Fujisue","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.cardfail.2023.06.024_bib0019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ejhf.2124","article-title":"Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial","volume":"23","author":"Butt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0020","article-title":"Meta-analysis of intensive lipid-lowering therapy in patients with polyvascular disease","volume":"10","author":"lkhalil","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8295054","article-title":"Burden of coronary artery disease and peripheral artery disease: a literature review","author":"Bauersachs","year":"2019","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018684","article-title":"Association of heart failure with outcomes among patients with peripheral artery disease: insights from EUCLID","volume":"10","author":"Samsky","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2023.06.024_bib0023","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.ackd.2014.07.005","article-title":"Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes","volume":"21","author":"Garimella","year":"2014","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423002750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423002750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:51:21Z","timestamp":1761029481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916423002750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1071916423002750"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.06.024","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}